FDA Inspection
AustarPharma, LLCAustarPharma, LLC – FDA Inspection, Dec 4, 2024
Record Details
This FDA Inspection record concerns AustarPharma, LLC, with an inspection on December 4, 2024, issued by the New Jersey District Office, covering human drugs.
View Company Profile
ID · 10e2a2db-5b56-49da-a13d-88339fba8141
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1236866
- FDA center
- Human Drugs
- Project area
- Postmarketing Surveillance and Epidemiology: Human Drugs
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 314.80(c)(2)Late submission of annual safety reports
- 21 CFR 314.80(c)(2)Late submission of quarterly safety reports
- 21 CFR 314.80(b)Failure to develop written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of AustarPharma, LLC
9| Date | Classification | Office | Project area |
|---|---|---|---|
| April 5, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 11, 2019 | Not classified | New Jersey District Office | |
| May 23, 2018 | VAI | New Jersey District Office | Generic Drug Evaluation |
| January 5, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 22, 2017 | Not classified | New Jersey District Office |
Other documents for AustarPharma, LLC
- FDA Inspection 1201798 - 2023-04-05
- FDA Inspection 1080178 - 2019-02-11
- FDA Inspection 1052925 - 2018-05-23
- FDA Inspection 1037881 - 2018-01-05
- FDA Inspection 1015357 - 2017-06-22
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.